Navigation Links
Clinical Data from NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
Date:12/13/2012

ommercializing novel immunotherapeutic products to improve treatment options for cancer patients. NewLink's portfolio includes biologic and small-molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. NewLink's lead product candidate, algenpantucel-L (HyperAcute Pancreas) is being studied in a Phase 3 clinical trial in surgically resected pancreatic cancer patients (under a Special Protocol Assessment with the U.S. FDA) as well as in a separate study in locally advanced pancreatic cancer patients. NewLink has recently launched an adaptive design Phase 2B/3 clinical trial of tergenpumatucel-L (HyperAcute Lung) in patients with non-small cell lung cancer. NewLink is developing indoximod (d-1-methyltryptophan, or D-1MT), a small-molecule, orally bioavailable product candidate from NewLink's proprietary indoleamine-(2, 3)-dioxygenase, or IDO, pathway inhibitor technology. NewLink is studying indoximod in various chemotherapy and immunotherapy combination studies independently and in collaboration with the National Cancer Institute. For more information please visit http://www.linkp.com. Patient information is available at http://www.pancreaticcancer-clinicaltrials.com

Safe Harbor Statement

This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan,""target," "pote
'/>"/>

SOURCE NewLink Genetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
5. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
8. First Patient Treated in U.S. Clinical Study of Cohera Medicals TissuGlu® Surgical Adhesive
9. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Sihuan Pharmaceutical Holdings ... "Company"), a leading pharmaceutical company with the largest ... China,s prescription drug market, today announced ... its subsidiaries (collectively the "Group") for the six ... Financial HighlightsFor the Six months ended 30 ...
(Date:8/27/2014)... BOSTON , Aug. 27, 2014  Columbia Laboratories, ... Company"), a provider of pharmaceutical development, clinical trial manufacturing, ... industry, today announced that it will participate at the ... Investment Conference, to be held in New ... conference at 11:15am on September 9, 2014 at the ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver ... on the Fatty Liver Disease clinical trial scenario. This ... clinical trials on Fatty Liver Disease . It ... recruitment status as per the site of trial conduction ... of disease clinical trials by their phase, trial status, ...
Breaking Medicine Technology:Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5
(Date:8/28/2014)... (PRWEB) August 28, 2014 Now in its ... that was started in 2011 by two brain aneurysm survivors. ... much needed awareness, provide education to help increase early detection ... impacted by a brain aneurysm. We hope that you will ... worthy cause at the 4th Annual Step for Hope Run/ ...
(Date:8/28/2014)... MMAR Medical is pleased to announce ... for regular customers to enjoy several perks and benefits ... a wholesale license. It’s a great choice for independent ... others who regularly purchase medical braces but could use ... own active lifestyle or those of your club, group ...
(Date:8/28/2014)... The revenue cycle process touches on ... time a patient books an appointment with a physician’s ... payments for services rendered to the healthcare provider. ... has the RCM process down to a science. Over ... common place in nearly every healthcare facility around the ...
(Date:8/28/2014)... August 28, 2014 UniVoIP, Inc, a ... Segundo, CA, today announced that they have been certified ... Los Angeles Local Small Business Enterprise (Local SBE) Preference ... certified by the state of California and LA county ... Cloud-hosted Telephony Solution to governmental agencies throughout the ...
(Date:8/27/2014)... 2014 Author and orthopedic surgeon William ... on the thrilling adventures of sharp and witty ... is gearing up for a new marketing push in ... novellas , “Prescription: Murder” follows the adventures of ... dodging assassination attempts and thwarting criminals. In the first ...
Breaking Medicine News(10 mins):Health News:Step for Hope and Raise Brain Aneurysm Awareness 2Health News:MMAR Medical Announces Customer Membership Program 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 3Health News:Cloud PBX Provider UniVoIP Gets Certified by the State of California and the County of Los Angeles Under the Local Small Business Enterprise (SBE) Preference Program 2Health News:William H. Simon Launches New Marketing Campaign for Book 2
... - Sunrise Senior Living and Conrad Properties Partner to Redefine Landmark ... Property Exclusively For Seniors ... SRZ ), an operator of more than 450 senior living communities,worldwide, ... 23- story Clayton on the Park hotel and apartments into an,exclusive ...
... entire Texas,Medical Board (TMB) and its officials have been ... Physicians and Surgeons (AAPS). The complaint,filed this week in ... performing its official duties, specifically:, 1. Manipulation of ... Violation of due process;, 4. Breach of privacy; ...
... Virginia, Dec. 21 Echo Healthcare,Acquisition Corp. ("Echo" ... check company, announced at its special meeting of ... Friday, December 28, 2007 for,stockholders to vote on ... ("XLNT") and the related matters set forth in ...
... Pa. and KENILWORTH, N.J., Dec. 21 ,Centocor, ... ) today announced,they have revised their 1998 ... of both REMICADE(R),(infliximab), an anti-tumor necrosis factor ... golimumab, Centocor,s next-generation,human, anti-TNF alpha therapy, which ...
... will ensure consumers, interests are considered, protected, HARRISBURG, ... are protected, acting Insurance Commissioner Joel,Ario today announced that ... part of its review of the proposed consolidation of,Independence ... is to see that consumers would be protected in,any ...
... team says , FRIDAY, Dec. 21 (HealthDay News) -- People with ... a study that adds to growing evidence of a link between ... analyzed leg and torso measurements, as well as blood samples, from ... , The blood samples were checked for levels of four liver ...
Cached Medicine News:Health News:Sunrise to Unveil New Residence for Seniors at Clayton on the Park 2Health News:Doctors' Group Sues Texas Medical Board for Misconduct; Cites Institutional Culture of Retaliation & Intimidation 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 4Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 5Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 2Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 3Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 4Health News:Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross 2Health News:Shorter Legs Might Boost Liver Risks 2
Button shape tip, round serrated handle, dull finish, overall length 130 mm....
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Medicine Products: